My NCBI | Sign In
RSS Settings
  • Search: Berk-Planken II[au]

Display Settings:

Format
Sort by

Send to:

Choose Destination

    Results: 2

    1.

    Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: a potential mechanism to lower plasma triglycerides.

    Dallinga-Thie GM, Berk-Planken II, Bootsma AH, Jansen H; Diabetes Atorvastatin Lipid intervention (DALI) Study Group.

    Diabetes Care. 2004 Jun;27(6):1358-64.PMID: 15161788 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Atorvastatin dose-dependently decreases hepatic lipase activity in type 2 diabetes: effect of sex and the LIPC promoter variant.

    Berk-Planken II, Hoogerbrugge N, Stolk RP, Bootsma AH, Jansen H; DALI Study Group.

    Diabetes Care. 2003 Feb;26(2):427-32.PMID: 12547874 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Search details

    » See more...

    Recent activity